Literature DB >> 1828387

Functional inactivation of Dermatophagoides spp. (house dust mite) reactive human T-cell clones.

R E O'Hehir1, B A Aguilar, T J Schmidt, S O Gollnick, J R Lamb.   

Abstract

Staphylococcal enterotoxins are able both to stimulate powerful polyclonal proliferative responses and to induce non-responsiveness of T lymphocytes expressing the appropriate T-cell antigen receptor V beta gene products. T-cell clones representative of the human response to house dust mite were identified that express either V beta 3 or V beta 6 gene products. The specificity of the latter was confirmed by serology. Pre-treatment of cloned V beta 3+ T cells with the Staphylococcus aureus enterotoxins B or C1 rendered them non-responsive to immunogenic challenge with their natural ligand, while retaining responsiveness to exogenous IL-2. Similarly, exposure of the V beta 6+ dust mite reactive T cells to the staphylococcal enterotoxin of the appropriate specificity, SEE, induced specific anergy. The development of non-responsiveness was associated with changes in the T-cell phenotypes. Downregulation of the T-cell receptor, Ti-CD3, was paralleled by enhanced expression of both CD2 and the IL-2 receptor, CD25. Differential co-modulation of CD4 and Ti-CD3 suggested that for some T cells CD4 may form part of the specific antigen recognition structure. Toxicity of the staphylococcal enterotoxins may be removed by chemical modification, thus their ability functionally to inactivate subpopulations of T cells expressing antigen-specific receptors with shared characteristics may be of potential value in the regulation of allergic diseases if the diversity of the T-cell repertoire proves to be limited.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1828387     DOI: 10.1111/j.1365-2222.1991.tb00832.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  10 in total

Review 1.  The potential of peptide immunotherapy in allergy and asthma.

Authors:  F Runa Ali; A Barry Kay; Mark Larché
Journal:  Curr Allergy Asthma Rep       Date:  2002-03       Impact factor: 4.806

Review 2.  How T cells recognise antigen: implications for lung diseases.

Authors:  R M du Bois
Journal:  Thorax       Date:  1992-02       Impact factor: 9.139

Review 3.  Clinical immunology.

Authors:  R J Powell
Journal:  Postgrad Med J       Date:  1991-11       Impact factor: 2.401

4.  Molecular basis of cross-reactivity among allergen-specific human T cells: T-cell receptor V alpha gene usage and epitope structure.

Authors:  S S Mohapatra; S Mohapatra; M Yang; A A Ansari; P Parronchi; E Maggi; S Romagnani
Journal:  Immunology       Date:  1994-01       Impact factor: 7.397

Review 5.  Cytokines. 3. Cytokines in asthma.

Authors:  D S Robinson; S R Durham; A B Kay
Journal:  Thorax       Date:  1993-08       Impact factor: 9.139

6.  Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses.

Authors:  V A Varney; Q A Hamid; M Gaga; S Ying; M Jacobson; A J Frew; A B Kay; S R Durham
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

Review 7.  Novel approaches in immunotherapy.

Authors:  J M Saint-Remy
Journal:  Clin Rev Allergy       Date:  1994

8.  Major histocompatibility complex independent clonal T cell anergy by direct interaction of Staphylococcus aureus enterotoxin B with the T cell antigen receptor.

Authors:  C R Hewitt; J R Lamb; J Hayball; M Hill; M J Owen; R E O'Hehir
Journal:  J Exp Med       Date:  1992-06-01       Impact factor: 14.307

Review 9.  Immunoregulatory T cell epitope peptides: the new frontier in allergy therapy.

Authors:  S R Prickett; J M Rolland; R E O'Hehir
Journal:  Clin Exp Allergy       Date:  2015-06       Impact factor: 5.018

10.  Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice.

Authors:  G F Hoyne; R E O'Hehir; D C Wraith; W R Thomas; J R Lamb
Journal:  J Exp Med       Date:  1993-11-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.